Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

On July 2, 2024, the "ADC High-Level Closed-Door Seminar," chaired by Vice President Yong Yang of China Pharmaceutical University and President Jin Li of Shanghai Gaobo Oncology Hospital, was grandly held in Shanghai. The seminar explored the current status and future of ADC development. During the event, Oncology Frontier interviewed Professor Baohui Han from the Shanghai Chest Hospital . Combining recent ASCO conference updates, Professor Han analyzed the efficacy results and safety management points of ADC treatment in NSCLC and shared insights on the future prospects of ADC development.
Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

Time rewards those who strive, and success comes to those who persevere. As 2023 draws to a close, the year has left behind many noteworthy achievements in China’s field of urology, especially in the areas of prostate cancer surgery and drug treatments. On this occasion, Urology Frontier interviewed Xu Zhang, Academician of the Chinese PLA General Hospital and a pioneer in laparoscopic techniques in China’s urological surgery. In this interview, he shared significant developments in surgical and medical treatments for prostate cancer over the past year.
Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions

Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions

In the realm of cellular therapy, CAR-NK technology is spearheading a new wave of treatment possibilities. Given the current state of cellular therapy in China, advancing technologies like CAR-NK has become crucial. At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the privilege of inviting Dr. Wenbin Qian from The Second Affiliated Hospital Zhejiang University School of Medicine to provide an in-depth analysis of the benefits and challenges of CAR-NK therapy, explore future research directions, and discuss new chapters in cellular therapy.
Dr. Guohong Han’s Team: Measuring Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

Dr. Guohong Han’s Team: Measuring Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

Portal hypertension is a severe complication of chronic liver disease, directly associated with clinical outcomes such as ascites and variceal bleeding. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment that significantly reduces portal pressure. Portal pressure gradient (PPG) is commonly used to assess portal pressure in patients undergoing TIPS. Recently, a study conducted by Dr. Guohong Han's team from Xi'an International Medical Center Hospital that published in the Journal of Hepatology, explored the optimal timing of measurement and hemodynamic target of PPG in cirrhotic patients with variceal bleeding undergoing covered stent TIPS. Dr. Yong Lv from Xijing Hospital is the first author of this article, and Dr. Guohong Han is the corresponding author.
Dr. Yue Lu: A Review and Update on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dr. Yue Lu: A Review and Update on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare malignancy of the hematopoietic system, is distinguished by its highly recognizable skin manifestations and complex pathophysiology, which continue to captivate the medical community's investigative spirit and challenge its resolve. Recently, Dr. Yue Lu from Lu Daopei Medical provided an in-depth analysis of BPDCN's origins, clinical presentation, diagnostic methods, and treatment advancements, shedding light on the cutting-edge developments in this field. The following article, based on his insights, has been prepared by Hematology Frontier for our readers.
News Express | Leukemia Research Highlights from Blood Reviews: A Six-Month Overview

News Express | Leukemia Research Highlights from Blood Reviews: A Six-Month Overview

The "News Express" column serves as a bridge between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to swiftly capture industry trends, ignite innovative thinking, and broaden their professional perspectives. Hematology Frontier carefully selects the latest hematological research findings from top global journals. Each article is a brilliant spark of science and clinical practice, delivering the latest advancements in hematology directly to you. Let knowledge know no boundaries, and let exploration never cease. We invite you to follow the column and join global hematology experts on a journey of scientific discovery! This special issue compiles notable leukemia research from the past six months in Blood Reviews. We invite you to explore these highlights.
WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology. At the WCLC conference, " Oncology Frontier" invited Dr. Han Baohui, Zhong Runbo, Zhang Wei, and Lu Jun from the affiliated Thoracic Hospital of Shanghai Jiao Tong University School of Medicine to engage in discussions on hot topics at the conference and important clinical research.
WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam's research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA's approval of a third-generation EGFR inhibitor for metastatic non-small cell lung cancer. Additionally He also led clinical and translational research on new immunotherapies for treating lung cancer , resulting in over 400 published, peer-reviewed publications. He also served on the IASLC board of directors (2017-2021) and the NCI Thoracic Malignancy Steering Committee (2012-2021). He is currently the chief editor of the journal 《Cancer》 published by the American Society of Clinical Oncology.